FibroGen China, a partner of AstraZeneca, has received marketing approval from the China's National Medical Products Administration for Roxadustat intended to treat anaemia in chronic kidney disease patients on dialysis, it was reported yesterday.
The product is a hypoxia-inducible factor prolyl hydroxylase inhibitor indicated to treat patients who use haemodialysis or peritoneal dialysis. It is intended to help induce coordinated erythropoiesis, increase red blood cell count and maintain plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease patients.
The approval was based on an open-label and active-control 26-week phase III trial in dialysis dependent- chronic kidney disease patients with anaemia who have been earlier treated with various forms of a generic erythropoiesis-stimulating agent. These patients were randomised to secure either roxadustat or epoetin alfa in the trial. AstraZeneca has collaborated with FibroGen China to develop and commercialise roxadustat in China.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical